GlassScriptPhysician profile
Lawrence Winton
NPI 1427011451
$1,371.16
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $196 · 2021: $465 · 2022: $198 · 2023: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $299.12 | 2020-2021 | |
| Janssen Biotech, INC. | $289.48 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $139.33 | 2021-2023 | Prolaris |
| Urovant Sciences INC | $101.42 | 2021-2022 | |
| Astellas Pharma US INC | $89.52 | 2019-2020 | |
| Bard Access Systems, INC. | $84.44 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $78.65 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $69.58 | 2019-2023 | Xiaflex, Edex, Aveed |
| Merck Sharp & Dohme LLC | $46.41 | 2021 | |
| Abbvie INC. | $42.51 | 2019-2022 | |
| Pfizer INC. | $36.55 | 2019-2022 | |
| 180 Medical, INC. | $27.17 | 2023 | Gentlecath |
| Bayer Healthcare Pharmaceuticals INC. | $23.26 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $16.15 | 2021 | |
| Coloplast Corp | $13.97 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $13.60 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Winton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.